Alexion Gets FDA Warning Over Contamination At RI Plant

Law360, Washington (March 28, 2013, 7:52 PM EDT) -- Alexion Pharmaceuticals Inc. was hit with a U.S. Food and Drug Administration warning letter Wednesday over a bacterial contamination investigation and other shortfalls at its Rhode Island manufacturing plant.

The company produces its only FDA-approved drug, the blood disorder treatment Soliris, at the facility, but could shut down manufacturing or shipment processes as it addresses the plant's shortfalls.

According to a U.S. Securities and Exchange Commission filing by Alexion, the FDA inspected the Rhode Island facility in August and determined the company's investigation into bacterial contamination...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.